Squarepoint
RLMD icon

Squarepoint’s Relmada Therapeutics RLMD Stock Holding History

Squarepoint’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$693K Buy
+183,943
New +$902K ﹤0.01% 3102
2026
Q2 		– Sell
-63,426
Closed -$441K – 4893
2026
Q1 		$441K Sell
63,426
-74,807
-54% -$354K ﹤0.01% 3405
2025
Q4 		$668K Buy
+138,233
New +$463K ﹤0.01% 2964
2024
Q3 		– Sell
-35,425
Closed -$106K – 4608
2024
Q2 		$106K Sell
35,425
-43,588
-55% -$158K ﹤0.01% 3786
2024
Q1 		$367K Buy
79,013
+5,579
+8% +$26.9K ﹤0.01% 3256
2023
Q4 		$304K Buy
73,434
+40,337
+122% +$119K ﹤0.01% 3350
2023
Q3 		$99.3K Sell
33,097
-45,923
-58% -$136K ﹤0.01% 3558
2023
Q2 		$194K Buy
+79,020
New +$218K ﹤0.01% 3232
2023
Q1 		– Sell
-35,281
Closed -$123K – 3724
2022
Q4 		$123K Buy
+35,281
New +$310K ﹤0.01% 2931
2021
Q1 		– Sell
-7,130
Closed -$229K – 3533
2020
Q4 		$229K Buy
+7,130
New +$245K ﹤0.01% 2419
2020
Q3 		– Sell
-8,106
Closed -$363K – 2786
2020
Q2 		$363K Buy
+8,106
New +$343K 0.01% 1483
2020
Q1 		– Sell
-8,918
Closed -$348K – 2404
2019
Q4 		$348K Buy
+8,918
New +$271K ﹤0.01% 1965

Other funds holding RLMD

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
DMKJ
David M. Knott Jr $183M AUM 73.23% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Parsons Capital Management
Parsons Capital Management Providence, Rhode Island $2.29B AUM 21.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Squarepoint's RLMD Position: Q3 2026 in Review

Squarepoint opened a new position in Relmada Therapeutics (RLMD) in Q3 2026: 183,943 shares worth $693K. The stake represents ﹤0.01% of the portfolio and ranks #3102 among its holdings. This is a return to the name: Squarepoint previously reported a position in RLMD as recently as Q1 2026.

Squarepoint first reported a position in RLMD in Q4 2019 and has held it in 12 quarters since. 60 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.

  • Squarepoint held 183,943 shares of Relmada Therapeutics worth $693K as of Q3 2026.
  • Relmada Therapeutics was a new Squarepoint position in Q3 2026.
  • Relmada Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3102 holding.
  • Squarepoint first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 12 quarters since.
  • 60 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.